Paradigm Biopharmaceuticals Ltd (ASX:PAR) will host a conference call at 9.00am AEDT tomorrow morning to present and discuss the results of its phase IIb clinical trial.
The trial evaluated the effects of iPPS on the treatment of pain in subjects with knee OA and concurrent subchondral bone marrow edema lesions.
Investors can pre-register for this conference and avoid a queue when calling here.
READ: Paradigm Biopharmaceuticals has results pending for phase 2b clinical trial
The company entered a trading halt last Friday in anticipation of releasing the trial results.
Shares in the company last traded at $1.32 before being halted.